V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10007211 | 10005051 | 1.7 | 56.4 | Neo-adjuvant (N) | 2018-06-24 | 2018-06-28 | Cisplatin + Doxorubicin | 02 | N | 10514463 | DABRAFENIB + TRAMETINIB |
| 10007212 | 10005053 | 1.7 | null | Disease modification (D) | null | 2017-02-24 | CISPLATIN + GEMCITABINE | 02 | N | 10514513 | CISPLATIN + FLUOROURACIL |
| 10007213 | 10005055 | 1.62 | 63.9 | Palliative (P) | 2016-05-01 | 2016-05-29 | MPT | 02 | N | 10514673 | TOPOTECAN |
| 10007214 | 10005059 | 1.59 | 60.7 | Palliative (P) | 2015-04-02 | 2015-04-27 | Trifluridine + Tipiracil | N | N | 10514873 | REMODL TRIAL |
| 10007215 | 10005061 | 1.7 | 84.6 | Adjuvant (A) | 2015-07-07 | 2015-07-21 | Bortezomib | 2 | N | 10514873 | CISPLATIN + RT |
| 10007216 | 10005061 | 1.64 | 0 | Palliative (P) | 2017-06-16 | 2017-06-18 | Capecitabine + Cisplatin + RT | N | N | 10514873 | RCEOP |
| 10007217 | 10005063 | 1.56 | 49.1 | Disease modification (D) | 2019-03-30 | 2019-04-01 | IMATINIB | 02 | N | 10515391 | DABRAFENIB + TRAMETINIB |
| 10007218 | 10005063 | 1.57 | 64 | Not known (9) | 2015-04-21 | 2015-04-27 | CARBOPLATIN + PACLITAXEL + RT | 02 | N | 10515391 | ERLOTINIB |
| 10007219 | 10005066 | 1.7 | 70.6 | Palliative (P) | 2017-08-10 | 2017-08-10 | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | N | N | 10515510 | CAPECITABINE + CISPLATIN + RT |
| 10007220 | 10005067 | 0 | 60 | Adjuvant (A) | 2018-10-21 | 2018-10-21 | FEC | 02 | N | 10515574 | CETUXIMAB + IRINOTECAN + MDG |
| 10007221 | 10005068 | 1.64 | 47 | Disease modification (D) | 2016-04-14 | 2016-04-17 | Epirubicin | 02 | N | 10515574 | CAPECITABINE + CARBOPLATIN |
| 10007222 | 10005069 | 1.66 | 89 | Disease modification (D) | null | 2018-09-11 | CYCLOPHOSPHAMIDE + ETOPOSIDE + LOMUSTINE | N | N | 10515683 | CYCLOPHOSPHAMIDE + ETOPOSIDE + RITUXIMAB |
| 10007223 | 10005070 | 1.64 | null | Palliative (P) | 2016-07-25 | 2016-08-04 | Erlotinib | N | N | 10515745 | LIPOSOMAL DOXORUBICIN |
| 10007224 | 10005070 | null | null | Palliative (P) | 2019-05-23 | 2019-07-24 | Ipilimumab | N | N | 10515745 | TEMOZOLOMIDE + RT |
| 10007225 | 10005070 | 1.6 | 68.9 | Adjuvant (A) | 2017-01-25 | 2017-02-03 | Cisplatin + Vinorelbine (PO) | N | Y | 10515745 | DABRAFENIB |
| 10007226 | 10005071 | 1.57 | 99 | Palliative (P) | 2017-11-08 | 2017-11-11 | EC | N | N | 10516284 | CETUXIMAB |
| 10007227 | 10005071 | 1.75 | 72 | Palliative (P) | 2018-03-31 | 2018-04-11 | Irinotecan | N | N | 10516284 | CETUXIMAB |
| 10007228 | 10005071 | 1.79 | 61 | Palliative (P) | 2015-03-01 | 2015-03-08 | Methotrexate High Dose (3g/m2) | 02 | N | 10516284 | REMODL TRIAL |
| 10007229 | 10005072 | 1.53 | 99 | Palliative (P) | 2018-03-14 | 2018-04-18 | DABRAFENIB + TRAMETINIB | 02 | N | 10516739 | FLUOROURACIL + MITOMYCIN + RT |
| 10007230 | 10005074 | null | 60 | Adjuvant (A) | null | 2018-06-15 | RUXOLITINIB | N | null | 10516754 | MELPHALAN |
| 10007231 | 10007541 | 1.75 | 134 | Curative (C) | 2015-05-06 | 2015-05-16 | AXITINIB | 2 | null | 10516791 | CYTARABINE |
| 10007232 | 10007542 | null | 68 | Palliative (P) | 2014-04-20 | 2014-05-01 | Bortezomib +/- Dexamethasone | null | null | 10516936 | IDELALISIB + RITUXIMAB |
| 10007233 | 10005077 | 1.66 | null | Palliative (P) | 2017-01-21 | 2017-02-04 | Docetaxel + Nintedanib | 2 | Y | 10517263 | CARBO + FLUOROURACIL |
| 10007234 | 10007543 | 2 | 60 | Palliative (P) | 2018-12-22 | 2018-12-29 | Capecitabine (14 day) + Irinotecan | N | N | 10517435 | FEC |
| 10007235 | 10005080 | null | 91 | Palliative (P) | null | 2015-12-04 | CYCLOPHOSPHAMIDE + GEMCITABINE + RITUXIMAB + VINCRISTINE | N | N | 10517595 | CETUXIMAB + IRINOTECAN + MDG |
| 10007236 | 10007544 | 1.62 | null | Palliative (P) | 2016-10-14 | 2016-10-14 | Cisplatin + Pemetrexed | 02 | N | 10517635 | TRIFLURIDINE + TIPIRACIL |
| 10007237 | 10007545 | 1.87 | 95 | Neo-adjuvant (N) | 2017-08-28 | 2017-08-31 | RITUXIMAB + IBRUTINIB | null | null | 10517854 | CISPLATIN + PEMETREXED |
| 10007238 | 10005085 | 1.76 | null | Curative (C) | 2017-05-06 | 2017-06-10 | DA-EPOCH | N | N | 10517995 | MYELOMA XI TRIAL |
| 10007239 | 10005085 | 1.65 | 69.5 | Palliative (P) | 2017-10-03 | 2017-10-10 | EOX | 02 | Y | 10517995 | EOX |
| 10007240 | 10005086 | 1.8 | 86.199 | Palliative (P) | 2017-01-29 | 2017-02-11 | Enzalutamide | N | null | 10518314 | CYCLOPHOSPHAMIDE + LENALIDOMIDE |
| 10007241 | 10005086 | 1.77 | 60 | Palliative (P) | 2018-01-04 | 2018-01-21 | GEM-P | N | N | 10518314 | CHLORAMBUCIL + OBINUTUZUMAB |
| 10007242 | 10005088 | 1.73 | 81.5 | Palliative (P) | 2018-06-03 | 2018-06-08 | Bortezomib +/- Dexamethasone | N | N | 10519073 | RADIUM 223 |
| 10007243 | 10005089 | null | 0 | Disease modification (D) | 2015-01-18 | 2015-01-22 | CISPLATIN + FLUOROURACIL | N | N | 10519110 | LIPOSOMAL DOXORUBICIN |
| 10007244 | 10005091 | null | null | Adjuvant (A) | 2018-10-04 | 2018-10-04 | CARBOPLATIN + RT | N | N | 10519170 | METHOTREXATE INTRATHECAL |
| 10007245 | 10005095 | null | null | Adjuvant (A) | 2018-03-22 | 2018-03-22 | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | N | N | 10519170 | CMF |
| 10007246 | 10005097 | 1.64 | 131.2 | Curative (C) | null | 2015-10-29 | Bortezomib + CYCLOPHOSPHAMIDE | null | null | 10519327 | CABAZITAXEL |
| 10007247 | 10005098 | null | 89.2 | Curative (C) | 2017-01-20 | 2017-02-01 | CETUXIMAB | 99 | Y | 10519461 | GDP |
| 10007248 | 10005099 | 1.72 | 97 | Curative (C) | 2015-03-09 | 2015-06-09 | Pazopanib | 02 | N | 10519461 | HCX |
| 10007249 | 10005100 | 1.82 | null | Adjuvant (A) | 2016-02-05 | 2016-02-28 | Liposomal Doxorubicin 50mg/m2 | 02 | N | 10519825 | BORTEZOMIB |
| 10007250 | 10005100 | 1.59 | 126.8 | Palliative (P) | 2018-04-11 | 2018-04-24 | Cisplatin + Pemetrexed | 2 | Y | 10519825 | FOCUS4 TRIAL |
| 10007251 | 10005101 | 1.74 | 96 | Palliative (P) | 2017-05-04 | 2017-07-02 | CAPECITABINE + EPIRUBICIN + OXALIPLATIN | N | N | 10520070 | SUNITINIB |
| 10007252 | 10005103 | 1.71 | 116.8 | Palliative (P) | null | 2018-04-30 | Methotrexate intrathecal | N | N | 10520115 | VINCRISTINE |
| 10007253 | 10005104 | 1.77 | 62.1 | Adjuvant (A) | 2015-08-04 | 2015-09-22 | PACIFICO TRIAL | N | N | 10520115 | ABVD |
| 10007254 | 10007557 | 1.75 | 50 | Adjuvant (A) | 2014-04-25 | 2014-04-28 | Fluorouracil+Mitomycin+RT (Bladder) | 2 | N | 10520212 | CARBOPLATIN + RT |
| 10007255 | 10007557 | null | 0 | Curative (C) | 2016-11-27 | 2017-01-01 | TOPOTECAN | 02 | N | 10520212 | CAPECITABINE + IRINOTECAN |
| 10007256 | 10005107 | 1.6 | null | null | 2017-10-05 | 2017-11-06 | Liposomal Doxorubicin 40mg/m2 | N | N | 10520306 | CARBOPLATIN + LIPOSOMAL DOX |
| 10007257 | 10005107 | 1.76 | 80 | Disease modification (D) | 2018-12-17 | 2019-01-20 | VISMODEGIB | N | N | 10520306 | CISPLATIN + GEMCITABINE |
| 10007258 | 10005108 | 1.88 | 69.55 | Adjuvant (A) | 2016-02-24 | 2016-02-25 | Hydroxycarbamide | 02 | Y | 10520519 | CARBO + FLUOROURACIL |
| 10007259 | 10005108 | 1.7 | 61.6 | Neo-adjuvant (N) | 2015-04-12 | 2015-04-19 | DOCETAXEL + TRASTUZUMAB | 02 | N | 10520519 | FEC |
| 10007260 | 10005110 | 1.69 | 90.5 | Disease modification (D) | 2017-08-12 | 2017-08-17 | IRINOTECAN + MDG + PANITUMUMAB | N | N | 10520720 | CETUXIMAB + IRINOTECAN |